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Phospholipase D inhibitors reduce human
prostate cancer cell proliferation and colony
formation
Amanda R Noble*,1, Norman J Maitland1, Daniel M Berney2 and Martin G Rumsby1
1Department of Biology, Cancer Research Unit, University of York, York YO10 5DD, UK and 2Department of Molecular Oncology,
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Background: Phospholipases D1 and D2 (PLD1/2) hydrolyse cell membrane glycerophospholipids to generate phosphatidic acid,
a signalling lipid, which regulates cell growth and cancer progression through effects on mTOR and PKB/Akt. PLD expression and/
or activity is raised in breast, colorectal, gastric, kidney and thyroid carcinomas but its role in prostate cancer (PCa), the major
cancer of men in the western world, is unclear.
Methods: PLD1 protein expression in cultured PNT2C2, PNT1A, P4E6, LNCaP, PC3, PC3M, VCaP, 22RV1 cell lines and patient-
derived PCa cells was analysed by western blotting. PLD1 protein localisation in normal, benign prostatic hyperplasia (BPH), and
castrate-resistant prostate cancer (CRPC) tissue sections and in a PCa tissue microarray (TMA) was examined by
immunohistochemistry. PLD activity in PCa tissue was assayed using an Amplex Red method. The effect of PLD inhibitors on
PCa cell viability was measured using MTS and colony forming assays.
Results: PLD1 protein expression was low in the luminal prostate cell lines (LNCaP, VCaP, 22RV1) compared with basal lines (PC3
and PC3M). PLD1 protein expression was elevated in BPH biopsy tissue relative to normal and PCa samples. In normal and BPH
tissue, PLD1 was predominantly detected in basal cells as well in some stromal cells, rather than in luminal cells. In PCa tissue, luminal
cells expressed PLD1. In a PCa TMA, the mean peroxidase intensity per DAB-stained Gleason 6 and 7 tissue section was significantly
higher than in sections graded Gleason 9. In CRPC tissue, PLD1 was expressed prominently in the stromal compartment, in luminal
cells in occasional glands and in an expanding population of cells that co-expressed chromogranin A and neurone-specific enolase.
Levels of PLD activity in normal and PCa tissue samples were similar. A specific PLD1 inhibitor markedly reduced the survival of both
prostate cell lines and patient-derived PCa cells compared with two dual PLD1/PLD2 inhibitors. Short-term exposure of PCa cells to
the same specific PLD1 inhibitor significantly reduced colony formation.
Conclusions: A new specific inhibitor of PLD1, which is well tolerated in mice, reduces PCa cell survival and thus has potential as a
novel therapeutic agent to reduce prostate cancer progression. Increased PLD1 expression may contribute to the hyperplasia
characteristic of BPH and in the progression of castrate-resistant PCa, where an expanding population of neuroendocrine-like cells
express PLD1.
Phospholipase D (PLD) hydrolyses major membrane glyceropho-
spholipids to phosphatidic acid (PtdOH), an intermediate in
complex lipid synthesis. PtdOH is also a key signalling lipid that
activates proteins at membrane surfaces (Kooijman et al, 2003) and
regulates cell survival (Foster, 2009). Due to its inverted cone
shape, PtdOH can also alter membrane curvature, facilitating the
vesicle formation (Yang et al, 2008) needed to increase tumour cell
proliferation.
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The PtdOH generated by PLD activity can regulate cell survival
and motility through mTOR, a master regulator of cancer cell
survival and growth, which controls protein synthesis, migration,
invasion and metastasis (Foster, 2009). PtdOH formation also
leads to inhibition of protein phosphatase 1 and upregulation of
the ERK, PKB/Akt, NFkB and Wnt signalling pathways, further
promoting both cancer cell survival and metastasis (Foster, 2009;
Winter et al, 2010; Kang et al, 2011; Yoon et al, 2011). Abnormal
activation of Wnt/b-catenin signalling and hyperactivation of
transcriptional target genes has been linked to prostate cancer
(PCa) and especially metastasis to bone in castration-resistant
disease (Hall and Keller, 2006; Yokoyama et al, 2014).
PLD1 and PLD2 are the two main isoforms of PLD in human
cells (Foster and Xu, 2003). PLD1 has a diffuse cytoplasmic
localisation (Freyberg et al, 2001) and is activated by protein kinase
C (PKC) (Kim et al, 2000), casein kinase-II (Ahn et al, 2006) and
by the small GTPases ARF and RHO (Foster, 2009). In contrast,
PLD2 is located at the plasma membrane and is activated by both
PKC and by receptor (EGFR, PDGFR) and non-receptor (Src,
JAK3) tyrosine kinases (Henkels et al, 2010). PLD2 has a higher
basal activity than PLD1 and acts as both a phospholipase and as a
guanine nucleotide exchange factor (Kang et al, 2014). Total PLD
activity is increased in gastric cancer (Uchida et al, 1999) and
breast cancer where levels correlate with disease grade (Uchida
et al, 1997). PLD1 is overexpressed in human breast cancer tissue
(Noh et al, 2000), while PLD2 expression is increased in renal
(Zhao et al, 2000) and thyroid carcinomas (Kim et al, 2008).
Expression of PLD2 is increased in colorectal cancer where it
correlates with tumour size and prognosis (Saito et al, 2007). In a
human breast carcinoma xenograft model, PLD2 drives cell
invasion, tumour growth and metastasis (Henkels et al, 2013).
Inhibition of either PLD1 or PLD2 also makes breast cancer cells
more susceptible to radiotherapy (Cheol Son et al, 2013). New
isoform-specific PLD inhibitors can reduce proliferation of breast
cancer cells in mice and are well tolerated (Henkels et al, 2013). If
similar overexpression of PLD is present, these new inhibitors have
potential as alternative therapeutic agents to hormone-based and
other current therapies used to treat PCa.
MATERIALS AND METHODS
Prostate epithelial cell lines. The prostate cell lines used with
their growth media requirement, diagnosis and origin are listed in
Table 1.
Patient-derived prostate epithelial and stromal cells. Primary
prostate epithelial and stromal cells were cultured from human
prostate tissues (Collins et al, 2001; Frame et al, 2016), which were
obtained with patient consent and full ethical approval (LREC:07/
H1304/121) from radical prostatectomies and transurethral resec-
tions of the prostate (TURPS). Histopathology information was
provided for pre- and post-operative samples as a Gleason grade,
or verifying morphology as normal. Epithelial cells were grown on
collagen 1-coated 10 cm dishes in KSFM with supplements of 1%
L-glutamine, bovine pituitary extract and epidermal growth factor
at 37 1C with 5% CO2. For the first passage, cells were co-cultured
with irradiated (60Gy) mouse embryonic fibroblast (STO) cells.
Subsequent passages were free of STOs and all cultures were used
at the lowest practical passage number after establishment in
culture (p2–p5). Stromal cells were cultured in RPMI 1640 with
10% FCS and 1% glutamine.
Western blotting. Epithelial cell lysates were prepared using
Cytobuster Protein Extraction Reagent (71009, EMD Millipore,
Watford, UK) with protease inhibitors (cOmplete, EDTA-free
Protease Inhibitor Cocktail Tablets, Roche, Burgess Hill, UK).
Stromal cell lysates were prepared in a 1% TX-100 lysis buffer
containing protease inhibitors. SDS-PAGE and western blotting
were as described previously (Rumsby et al, 2011). Primary
antibodies were an anti-PLD1 rabbit polyclonal (sc25512, Santa
Cruz, Insight Biotechnology, Wembley, UK, 1 : 750), and a rabbit
anti-GAPDH polyclonal (Abcam, Cambridge, UK, ab9485,
1 : 20 000). The secondary antibody was HRP-linked anti-rabbit
IgG (7074S, Cell Signalling, New England Biolabs Ltd, UK,
1 : 6000). A kaleidoscope protein ladder (Bio-Rad, Watford, UK,
Cat No 1610375) was used throughout.
PLD activity. PLD activity was measured with an Amplex Red
PLD kit (A12219, Invitrogen, Fisher Scientific Ltd, Loughborough,
UK) according to the manufacturer’s instructions. Prostate tissue
was chopped in the supplied buffer containing 1% peroxide-free
Triton X-100 and protease inhibitors. The chopped tissue in buffer
was put through three freeze/thaw cycles at  80 1C, homogenised
and centrifuged at 1000 g and 4 1C for 5min to remove cell debris.
The supernatant was used for analysis. PLD activity was assayed
with 50mg supernatant protein (measured by a bicinchoninic acid
[BCA] method) in triplicate, where sufficient tissue was available.
PLD from Streptomyces chromofucus (P0065, Sigma Aldrich
Company Ltd, Poole, UK) was used to produce a new standard
curve for every set of measurements.
PLD inhibition and cell viability. The effects of PLD inhibition
on the viability of prostate epithelial cell lines and patient-derived
PCa cells was measured using an MTS ([3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium) assay (Promega, Southhampton, UK). Wells of a 96-well
plate were filled with 100 ml of appropriate medium or medium
containing DMSO vehicle or different PLD inhibitors over a 1–
25 mM concentration range. A total of 1 104 cells were then
added. After 24 and 48 h treatment, cell viability was measured by
adding 12 ml MTS and incubating at 37 1C for 2 h prior to reading
absorbance at 490 nm. The dual PLD1/PLD2 inhibitor FIPI was
from Tocris, Bio-Techne Ltd, Abingdon, UK. Another dual PLD1/
PLD2 inhibitor 5W0 (VU0155056) and the specific PLD1 inhibitor
EVJ (VU0359595) were gifts from Prof Alex Brown, Vanderbilt
University, USA (Lavieri et al, 2009; Lewis et al, 2009; Lavieri et al,
2010).
Colony recovery assays. Patient-derived PCa cells were seeded in
collagen 1-coated 6 well plates at 2 105 cells per well in complete
KSFM medium. The following day, cells were treated with either
vehicle (DMSO) or a PLD inhibitor (17.5 mM) for 4 h. Cultures
were then rinsed, trypsinised, counted and seeded at 500 cells per
well of collagen 1-coated 6 well plates with STO feeder cells (Frame
et al, 2013). The complete KSFM medium was changed regularly
and further STOs added when required. After 2–3 weeks, colonies
of 432 cells (at least 5 population doublings) were scored after
being visualised by staining with 1% crystal violet in 10% ethanol
in PBS.
Immunohistochemistry. Sections of formalin-fixed paraffin-
embedded normal, benign prostatic hyperplasia (BPH) and
castrate-resistant prostate cancer (CRPC) tissue were warmed on
a slide drier for 20min at 45 1C, rehydrated through xylene and
ethanol and then processed in a 2100 antigen-retriever (Aptum
Biologics, Southampton, UK) for a two hour cycle in 10mM
sodium citrate buffer, pH6 containing 0.05% Tween-20. For
immunoperoxidase staining, slides were then rinsed three times
in phosphate-buffered saline (PBS), blocked with 10% foetal calf
serum (FCS) in PBS for one hour at room temperature (RT) and
incubated with primary antibodies in 10% FCS in PBS overnight at
4 1C or for 2 h at RT. Sections were rinsed three times in PBS,
treated with 3% hydrogen peroxide in PBS for 30min to remove
endogenous peroxidases and rinsed well in PBS. Secondary
biotinylated antibody in 10% FCS in PBS was then added for
30min at room temperature followed by thorough rinsing in PBS.
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Finally, sections were treated with streptavidin-HRP in 10% FCS in
PBS for 30min at room temperature. After three rinses, sections
were incubated with diaminobenzidene buffer (Vector kit or Sigma
tablets) followed by extensive rinsing in PBS. Sections were
counterstained with haematoxylin, rinsed with water and dehy-
drated through ethanol to xylene and mounted with DPX (Sigma
Aldrich Company Ltd).
For immunofluorescence (IF), tissue sections were blocked with
10% FCS in PBS and incubated with primary antibody overnight at
4 1C in 10% FCS in PBS followed by further rinses. Secondary
antibody in 10% FCS in PBS was added for 1 h followed by rinses.
Slides were mounted using Vectashield with DAPI to define nuclei
(Vector laboratories, Peterborough, UK) and examined using a
Nikon Eclipse TE300 fluorescence microscope (Nikon, Surrey,
UK). Antibodies used were a polyclonal anti-PLD1 (sc25512) at
1 : 100, an anti-p63 (Dako M7317, Agilent Technologies, Stockport,
UK) at 1 : 100, an anti-AMACR at 1 : 100 (Dako M3616), an anti-
chromogranin A at 1 : 400 (Invitrogen LK2H10 Fisher Scientific
Ltd), a goat anti-rabbit immunoglobulin/biotinylated (Dako
E0432) at 1 : 500 and a rabbit anti-mouse immunoglobulin/
biotinylated (Dako E0354) at 1 : 200. Streptavidin-HRP (Dako,
P0397) was used at 1 : 100.
Tissue microarray immunohistochemistry. A tissue microarray
(TMA) of 41 kidney and 168 PCa tissue sections Gleason graded 6
(n¼ 43), 7 (n¼ 97), 8 (n¼ 13) or 9 (n¼ 15) from the Barts Cancer
Institute was immunoperoxidase-stained for PLD1 as above.
Stained sections were then scanned using a Zeiss AxioScan.Z1
slide scanner (ZEN 2012 software) with a Plan Apochromat 20 /
0.8 objective. The composite.czi files were loaded into Tissue
Gnostics, GmbH, HistoQuest software (V 3.5.3) for analysis. The
intensity of DAB staining was quantified using the workable area
(mean 0.3mm2) of each tissue section. The results were analysed in
a GraphPad Prism statistical package (Graphpad Software, CA,
USA).
RESULTS
PLD1 protein expression in prostate cell lines. With equal
protein loadings (30 mg), basal-like prostate epithelial cell lines
PNT2C2, PNT1A, P4E6, and PC3 showed higher PLD1 protein
expression than the luminal-like cell line LNCaP (Figure 1A). Two
other luminal-like prostate epithelial cell lines VCaP and 22RV1
also expressed lower PLD1 protein compared with basal cell lines
PNT2C2 and PC3 (Figure 1B). PLD1 protein expression in the
metastatic PC3M cell line was much lower than in its parent cell
line PC3.
PLD1 protein expression in patient-derived prostate epithelial
and stromal cells. Cultured epithelial cells from Gleason 7 patient
biopsies (Figure 2A) expressed PLD1 as did cells derived from
prostate biopsies deemed to be normal (N) on pathological
examination. PLD1 protein expression was usually higher in cells
from Gleason 7 samples compared with cells from normal tissue
but differences did not achieve statistical significance. Prostate
epithelial cells derived from benign prostatic hyperplasia (BPH)
tissue consistently had higher levels of PLD1 protein relative to
cells from both normal and Gleason 7 prostate biopsies
(Figure 2B). Stromal cells cultured from GL7 and GL9 tissue
samples frequently expressed more PLD1 protein than the PC3 cell
line or stromal cells purified from PCa tissue graded GL6
(Figure 2C).
PLD activity. Determination of PLD activity on tissue samples
using the Amplex Red method gave results indicating that BPH,
Table 1. Details of cell lines, diagnosis, source and media requirements
Cell line Diagnosis Source/references Culture medium
PNT2C2 Normal prostate
epithelium
Obtained from ECACC (no longer available) RPMI 1640þ 10% foetal calf serum (FCS)þ1%
L-glutamine
PNT1A Normal prostate
epithelium
Kind gift to NJM’s lab from P. Berthon. Currently available from
Health Protection Agency Culture Collections.
RPMI 1640þ 10% FCSþ1% L-glutamine
P4E6 Prostate cancer Derived in York. Currently available from Health Protection Agency
Culture Collections
KSFMþ1% L-glutamine, bovine pituitary extract,
epidermal growth factor and 2% FCS
LNCaP Prostate cancer ATCC RPMI 1640þ 10% FCSþ1% L-glutamine
22RV1 Prostate cancer
from a xenograft
RRIR: CVCL_1045 RPMI 1640þ 10% FCSþ1% L-glutamine
VCaP Prostate cancer
bone metastasis
ATCC RPMI 1640þ 10% FCSþ1% L-glutamine
PC3 Prostate cancer
bone metastasis
ATCC Hams F12þ7% FCSþ 1% L-glutamine
PC3M Prostate cancer
bone metastasis
RRID:CVCL_9555 Hams F12þ7% FCSþ 1% L-glutamine
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Figure 1. PLD1 protein expression in prostate epithelial cell lines.
(A) PLD1 protein expression in normal and tumourigenic prostate
epithelial cell lines. (B) PLD1 protein expression in luminal cell lines
LNCaP, 22RV1 and VCaP. With all samples 30mg protein were resolved
by SDS-PAGE for western blotting with detection of GAPDH as a
loading control. Markers are kDa. Blots shown are representative of
several repeats. See Materials and Methods section for details.
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normal, and PCa tissue samples have similar levels of PLD activity
(Figure 3). Error bars shown are the standard deviation (n¼ 3).
The results without error bars are single results due to a limited
amount of fresh biopsy tissue.
PLD inhibitors reduce cell viability in prostate epithelial cell
lines. Changes in cell viability due to the actions of the dual PLD1/
PLD2 inhibitors FIPI and 5W0 (VU0155056) and a PLD1-specific
inhibitor EVJ (VU0359595) were evaluated after 24 and 48 h
treatment (Figure 4A). All three inhibitors reduced the viability of
prostate epithelial cell lines. The specific PLD1 inhibitor (EVJ) was
the most effective since at 25 mM it reduced cell viability to almost
zero after 48 h treatment. Cellular IC50 values calculated from the
MTS results using GraphPad prism (Table 2) confirmed that FIPI
and 5W0 were not as effective at reducing cell viability as the
specific PLD1 inhibitor EVJ.
PLD inhibitors reduce cell viability in patient-derived prostate
epithelial cells. All the inhibitors reduced the viability of patient-
derived epithelial cells over the 0–25 mM concentration range
studied (Figure 4B). Again, the specific PLD1 inhibitor was more
effective at reducing cell viability than FIPI and 5WO, especially
with cells from patient 1 though in neither case was cell viability
reduced to zero with 25 mM EVJ, some 20% of the cell population
still remaining viable after 48 h treatment. Cellular IC50 values
(Table 2) confirmed this finding.
PLD inhibitors reduce colony forming ability in patient-derived
prostate cells. Exposure of cells from tissue from eight different
PCa patients to 17.5 mM EVJ for 4 h significantly (P¼o0.001)
reduced subsequent colony formation (432 cells) relative to
DMSO vehicle controls (Figure 5) measured 2 weeks later. The
median reduction relative to controls by the PLD1 inhibitor EVJ
was about 30%. Of the eight patient samples treated with EVJ, five
showed a uniform 25% reduction in colony-forming ability while
three were more seriously affected.
PLD1 localisation in BPH tissue sections. Serial sections of BPH
tissue were stained for PLD1, p63 as a positive control for basal
cells and DAPI to reveal all cell nuclei. By IF, PLD1 protein was
detected as perinuclear punctate staining predominantly in basal
cells around prostate acini (Figure 6A, PLD1, arrows) compared
with the nuclear p63 positive control (Figure 6A, p63, arrow). The
merged images show that PLD1 is predominately expressed in
basal cells. The enlarged IF image in Figure 6B (arrows) reveals the
perinuclear punctate staining of PLD1 in the basal cells. This
localisation of PLD1 to basal cells in BPH tissue was confirmed by
immunoperoxidase staining. As shown in Figure 6C, PLD1-
positive cells (arrows) matching the distribution of the basal cell
marker p63 underlie a layer of light blue luminal cells lining the
duct. Both immunohistochemical approaches revealed that some
stromal cells in BPH tissue expressed PLD1.
PLD1 localisation in normal and tumourigenic prostate tissue
samples. In tissue sections from a normal biopsy, PLD1 expres-
sion was detected by IHC in the nuclei and cytoplasm of rounded
and elongated cells throughout the stroma, as well as prominently
in basal cells round defined glands (Figure 7B, arrows). Lower
PLD1 protein expression was also detected in luminal cell nuclei
and cytoplasm (Figure 7B, arrow). In sections from a biopsy core
graded Gleason 7, PLD1 protein was detected in elongated cells
throughout the stroma as well as in the cytoplasm and nuclei of
luminal cells (Figure 7C, arrows). In serial sections, these elongated
PLD1-positive stromal cells also expressed smooth muscle actin
(not shown). In CRPC tissue, PLD1 expression was detected in the
cytoplasm and nuclei of many stromal cells (Figure 7D, arrows)
and prominently in the cytoplasm of tightly packed cells (Figure 7D,
*) that, in serial sections, stained positively for chromogranin A
(Figure 7E *). A second antibody control of morphologically normal
prostate tissue showed no peroxidase staining (Figure 7A).
PLD1 expression in a PCa tissue microarray. All PCa tissue
sections graded Gleason 6–9 on a TMA showed PLD1 expression
in the cytoplasm and nuclei of luminal cells in glands, some of
which contained crystalloids (not shown). PLD1 expression was
detected in scattered cells throughout the stroma in all sections
examined. Some luminal cells showed intense PLD1 staining at
their apical surfaces. Quantitative and statistical analysis using the
GraphPad package revealed that the median peroxidase staining
intensity of GL6 and GL7 sections was significantly (*Po0.05)
higher than that of GL9 sections (Figure 8). Control kidney tissue
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Figure 2. PLD1 protein expression in patient derived prostate cells.
(A) PLD1 protein expression in epithelial cells derived from normal,
BPH and Gleason 7 prostate tissue. (B) PLD1 protein expression in
epithelial cells derived from normal and benign prostatic hyperplasia
tissue. (C) PLD1 protein expression in stromal cells purified from
prostate cancer tissue compared with PC3 cells. With all samples 30mg
protein were resolved by SDS-PAGE for western blotting with GAPDH
as loading control. Markers are kDa. Blots shown are representative of
several repeats. See Materials and Methods section for details. In
Figure 2A and C, PC3 cells were included as a positive control for PLD1.
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Figure 3. PLD activity in normal, BPH and Gleason-graded PCa tissue.
Patient biopsy samples were extracted and analysed using a commercial
Amplex Red PLD assay. 50mg total protein were assayed per sample.
Error bars on BPH and GL9 samples are standard deviation where
triplicate measurements were made or on normal, GL6 and GL7 samples
are a range where only duplicate readings were made per sample due
to limited availability of tissue. Lack of an error bar for one GL7 sample
is because there was only sufficient biopsy tissue for a single reading.
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sections on the TMA showed positive PLD1 staining in epithelial
layer cells lining most tubules.
DISCUSSION
The current consensus that PLD is involved in tumourigenesis
(Jenkins and Frohman, 2005; Cazzolli et al, 2006; Wang et al, 2006;
Foster, 2009; Winter et al, 2010; Kang et al, 2011; Henkels et al,
2013; Brown et al, 2017) has stimulated the development of
new inhibitors specific for PLD1 and PLD2 that are well
tolerated in mice (Scott et al, 2009). Although it is the major
cancer of men in the Western world, surprisingly little is
known about the expression and activity of PLD1 and PLD2
in PCa. In this first report on PLD isoforms in PCa, we have
investigated PLD1 using a commercial anti-PLD1 antibody
(sc-25512), which has been validated for western blotting (Disse
et al, 2009; Scott et al, 2009; Chen et al, 2013) and which has also
been used to detect PLD1 in cells by immunofluorescence (Disse
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Figure 4. Effect of PLD inhibitors on prostate epithelial cell viability. (A) prostate cell lines, (B) patient-derived prostate epithelial cells. The cells
were cultured with 0–25mM concentrations of the dual PLD1/PLD2 inhibitors FIPI and 5W0 and the PLD1-specific inhibitor EVJ. Inhibitors were
dissolved in DMSO. Cell viability was measured by MTS assay after 48 h. Results are expressed as percentage cell viability relative to DMSO
controls.
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et al, 2009; Han et al, 2011). We have not examined PLD2
expression in this work since, in agreement with Scott (Scott et al,
2009), we have found commercial anti-PLD2 antibodies to be
unreliable.
PLD1 protein expression in prostate epithelial cell lines. We
used the same panel of prostate epithelial cell lines as previously
(Rumsby et al, 2011; Schmitt et al, 2014) to examine PLD1 protein
expression in cells spanning the normal to metastatic extremes of
PCa (Figure 1A). We added PC3M cells, a more metastatic cell line
derived from PC3 cells. The finding that PLD1 protein expression
was lower in PC3M cells compared with the parent PC3 cell line
suggests that a PLD1-PtdOH-mTOR pathway may be less
important for metastasis in prostate epithelial cells compared with
other reported pathways such as an oncogene-tumour suppressor
cascade (Min et al, 2010), DNA-PKcs-Mediated Transcriptional
Regulation (Goodwin et al, 2015) and/or the tumour microenvir-
onment (Mlecnik et al, 2016). Luminal LNCaP cells expressed the
lowest levels of PLD1 compared with the basal cell lines especially
PC3 cells. This prompted us to check PLD1 protein expression in
two other luminal prostate cell lines, 22RV1 derived from a tumour
xenograft and VCaP derived from a PCa bone metastasis
Table 2. Inhibitor IC50 values for FIPI, 5W0 and EVJ effects on
cell viability as calculated from the MTS assay results using a
Prism package
Inhibitor IC50 values (lm)
Cell type FIPI 5W0 EVJ
PNT2C2 28.2 60.4 17.3
PNT1A 27.1 56.8 4.7
P4E6 13.6 10.9 9.4
LNCaP 32 24.6 14.3
PC3 19.3 27.3 9.8
PC3M 42.9 29.8 8.0
Patient 1 57.6 39.8 14.8
Patient 2 30.1 13.9 12.0
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Figure 5. Effect of PLD1 inhibitor on colony recovery in patient-
derived prostate epithelial cells. Patient-derived cells cultured from
prostate cancer biopsies were treated with 17.5mM EVJ (PLD1 inhibitor)
for 4 h prior to re-plating cells at low density without inhibitor with STO
feeder cells. Two weeks later, colonies of 432 cells were counted and
their number expressed relative to controls (DMSO vehicle only). A
Mann–Whitney test gave a significance of ***Po0.001. See Materials
and Methods section for details.
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Figure 6. PLD1 is expressed in basal cells in BPH tissue.
(A) Immunofluorescence: DAPI staining for nucleii, p63 marker for basal
cells, PLD1 (arrows indicate perinuclear PLD1 staining), and merged
images (scale bars 100mM). (B) IF PLD1 in BPH tissue showing the
perinuclear punctate pattern of expression (scale bar 90mM)
(C) Immunoperoxidase: BPH tissue stained for the basal cell marker p63
(arrows) and PLD1 (arrows). Scale bars: 50mM. See Materials and
Methods section for details of techniques.
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(Figure 1B). The finding that both had very low PLD1 protein
expression similar to LNCaP cells reveals that basal and luminal
prostate epithelial cell lines differ significantly in PLD1 protein
expression.
This difference helps explain our previous results (Rumsby et al,
2011), where activation of protein kinase C (PKC) markedly
stimulated choline headgroup release due to PLD1 activity in basal
PC3 cells, while luminal LNCaP cells showed a very weak response.
The difference would also explain our subsequent results (Schmitt
et al, 2014) where stimulation of PKC in PC3 cells, but not in
LNCaP cells, resulted in a rapid release of ethanolamine to the
culture medium due to an increased turnover of ethanolamine
phospholipids by PLD1. Our earlier results thus support this new
finding that basal and luminal prostate epithelial cell lines differ
significantly in their levels of PLD1 expression.
PLD1 protein expression in cells purified from prostate tissue.
Biopsy cores from different lobes of the prostate frequently show
PCa in one lobe and no cancer in the other. We exploited such
differences to isolate epithelial cells from biopsies of the same
patient’s prostate, which had been classified as malignant or non-
malignant (normal). All cells whether cultured from non-
malignant or malignant biopsy cores, or from TURPS (BPH or
high Gleason samples) expressed PLD1 at levels that were usually
lower than detected in the basal PC3 cell line. These biopsy-derived
epithelial cell cultures are predominately basal in phenotype since
stromal and luminal cells are removed during preparation (Collins
et al, 2001; Frame et al, 2016). PLD1 expression varied
considerably (Figure 2A) between cell preparations cultured from
PCa tissue of a similar Gleason grade. It was not routinely higher in
cultures derived from malignant prostate biopsies as reported for
some other cancers (Uchida et al, 1997; Uchida et al, 1999; Noh
et al, 2000; Zhao et al, 2000; Saito et al, 2007). Such differences in
PLD1 protein expression between cells isolated from PCa tissue of
similar Gleason grade probably reflect inter-patient and biopsy
variation. Significantly, however, epithelial cells cultured from BPH
tissue consistently showed higher PLD1 protein expression
compared with cells cultured from non-malignant or PCa tissue
(Figure 2B). In BPH, basal, luminal and stromal cell numbers
increase in the periurethral transition zone of the prostate
(Dermer, 1978; Bonkhoff et al, 1994; Roehrborn, 2008; Rane
et al, 2016) because of increased proliferation, or impaired
programmed cell death, from the influence of androgens,
oestrogens and reactive stromal growth factors (Roehrborn, 2008;
Schauer and Rowley, 2011). The increased PLD1 protein expres-
sion we observe in these basal cell cultures could enhance the
cellular proliferative changes observed in BPH tissue. This is
because stromal growth factors such as EGF and IGF can stimulate
PKC (Griner and Kazanietz, 2007; Lemmon and Schlessinger,
2010; Dowling and Kiely, 2015) thereby activating PLD1 and
increasing PtdOH formation and mTOR signalling (Foster, 2009;
Zhou and Huang, 2011).
*
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Figure 7. PLD1 protein expression in normal and tumourigenic prostate tissue. (A) Secondary antibody control, normal prostate tissue, (B) typical
PLD1 expression in normal prostate tissue, (C) PLD1 expression in Gleason 7 PCa tissue, (D) PLD1 expression in castrate-resistant PCa tissue and (E)
serial section of tissue in (D) showing cells staining positive for chromogranin (A) (*). Scale bar: (A–D) 50mM, (E) 100mM. See Materials and Methods
section for details of techniques.
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PLD1 protein expression in non-malignant, malignant and BPH
prostate tissue. Our IF and IHC results show that PLD1 is
preferentially expressed in basal rather than luminal epithelial cells
in situ in non-malignant and BPH tissue (Figures 6 and 7) in
agreement with western blot results on cells. Basal cells expressing
PLD1 are not observed in malignant tissue (Figure 7C) where
proliferative luminal cells predominate (Jonathan and Epstein,
2008). The increased PLD1 expression observed in the expanding
luminal compartment detected in PCa tissue (Figure 7C) may be
regulating part of this proliferation process. If so, the TMA results
suggest that PLD1 expression may play a more significant role in
prostate tumours graded Gleason 6 or 7 compared with the more
severe Gleason 9 stage. This agrees with our finding that more
metastatic PC3M cells had lower levels of PLD1 expression than
the less metastatic PC3 parental cell line.
The perinuclear punctate distribution of PLD1 in the cytosol of
prostate basal cells as revealed by IF (Figure 6B) is in keeping with
results by others using IF and overexpression methods (Brown
et al, 1998; Cockcroft, 2001; Freyberg et al, 2001; Lucocq et al,
2001; Du et al, 2003; Disse et al, 2009; Han et al, 2011) or other
anti-PLD1 antibodies (Freyberg et al, 2001; Vitale et al, 2001).
These results suggest a role for PLD1 in regulated exocytosis
involving lysosomes and endosomes and the generation of PtdOH
for second messenger effects at the plasma membrane notably on
mTOR and Raf (Foster et al, 2014). Our IHC detection of PLD1 in
the nucleus of stromal and luminal cells in PCa is significant
because nuclear PLD1 can activate a local nuclear PKCa and ERK
signalling pathway to stimulate cell proliferation (Jang and Min,
2012). This can be regulated by several cell surface signalling
pathways (Baldassare et al, 1997; Gayral et al, 2006; Ushio-Fukai,
2006; Jang and Min, 2012). Nuclear PLD1 is also linked to
diacylglycerol formation, which regulates entry of PKC isoforms
into the nucleus with effects on cell proliferation, gene expression
and malignancy (Martelli et al, 2004; Tu-Sekine and Raben, 2004;
Martelli et al, 2006). Stroma in non-malignant prostate tissue
contains mainly smooth muscle cells (Hagglof and Bergh, 2012)
and our finding that such cells co-express PLD1 is not surprising
since vascular smooth muscle cells also express PLD1 (Gayral et al,
2006). However, detection of PLD1 in CRPC, an incurable and
aggressive terminal stage of PCa (Katsogiannou et al, 2015), is
intriguing. Stromal cells that express PLD1 (Figures 2C and 7) also
express smooth muscle actin so are likely to be myofibroblasts
(Figure 7D) as smooth muscle cells decline in CRPC (Hagglof and
Bergh, 2012). Such cells secrete a variety of growth factors (Hagglof
and Bergh, 2012), which will activate PLD1 stimulating local cell
proliferation. In CRPC tissue, these growth factors may also
influence proliferation of the densely packed cells, which express
PLD1 in their cytoplasm (Figure 7D and E*). We showed that these
cells co-express chromogranin A (CgA), a marker for neuroendo-
crine cells (Deftos et al, 1996; Sun et al, 2009) and thus show focal
neuroendocrine differentiation (Terry and Beltran, 2014). We find
that similar PLD1-expressing cells in CRPC tissue also co-express
neurone-specific enolase (NSE), another neuroendocrine cell
marker (Deftos et al, 1996; Sun et al, 2009). These CgA- and
NSE-expressing neuroendocrine-like cells are indicative of a poor
prognosis (Terry and Beltran, 2014) and may arise from
adenocarcinoma cells by neuroendocrine transdifferentiation
involving IL-6 among other factors (Terry and Beltran, 2014;
Grigore et al, 2015). PLD1 in the cytosol of these neuroendocrine-
like cells may play a role in exocytosis important for cell
proliferation (Vitale et al, 2001) and may also regulate cell growth
through the generation of PtdOH and its links to Wnt signalling
pathways (Kang et al, 2011).
PLD activity. The anomaly that PLD1 protein expression in BPH
tissue samples is higher than in normal or PCa tissue, while PLD
activity in the two BPH tissue samples measured is not raised
above values for normal and PCa tissue may arise for two reasons.
Firstly, PLD1 protein expression was measured in cultured cells
from BPH tissue that are largely basal in phenotype, while PLD
activity was assayed in whole BPH tissue samples which contain
stromal and luminal cells as well as basal cells (Schauer and
Rowley, 2011). Secondly, any nuclear PLD1 detected in BPH tissue
by IHC would not have been assayed since these organelles would
be removed during centrifugation to pellet cell debris. With these
caveats, our activity results suggest that, unlike in breast
adenocarcinomas and other cancers (see Introduction), PLD
activity in PCa is not raised compared to normal tissue.
PLD inhibition. The potent effects of the new generation of PLD1
and PLD2 inhibitors (Monovich et al, 2007; Lavieri et al, 2009;
Lewis et al, 2009; Scott et al, 2009; Lavieri et al, 2010) on cell
survival show the importance of PLD isoforms in controlling
prostate epithelial cell proliferation (Foster, 2009; Winter et al,
2010; Kang et al, 2011; Yoon et al, 2011). It should be noted that
our IC50 values (Table 2) are higher than those reported for the
specific inhibition of PLD1 (Scott et al, 2009; Lavieri et al, 2010).
This is because our cells were cultured in serum-containing
medium under which conditions greater than 95% of these
lipophilic inhibitors can become protein bound (Lavieri et al, 2010;
Mathews et al, 2015). Our inhibitor concentrations in the mM
range are in agreement with other reports for the effects of these
PLD inhibitors on cells growing in serum-supplemented medium
(Lavieri et al, 2010; Liu et al, 2013; Mathews et al, 2015). Mathews
et al (2015) report that at 5–10 mM sufficient inhibitor is still
available for subtype-selective inhibition of PLD1 in cells growing
in serum-supplemented medium. The IC50 values in Table 2
indicate that basal PC3 cells are more sensitive to PLD inhibitors
than luminal LNCaP cells presumably because they express more
PLD protein. The cells from two Gleason 7 patient tissues growing
in serum free medium plus additives are also sensitive to the
specific PLD1 inhibitor. Their IC50 values are similar to those for
metastatic PC3 and PC3M cells because such patient derived
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Figure 8. Quantification of DAB stain intensity of PLD1 protein in
relation to Gleason grade in a tissue microarray. Over 150 PCa tissue
sections were analysed for PLD1 expression in a tissue microarray as
described in Materials and Methods section. Tissue sections graded
GL6 and 7 have a significantly higher mean peroxidase stain intensity
compared with GL9 sections (*Po0.05).
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prostate cells are often more resistant to treatments than cell lines
(Ulukaya et al, 2013; Butler et al, 2017). We are now investigating
the effects of the specific PLD2 inhibitor JWJ (VU0364739) on
prostate cancer cell survival since this isoform has both enzymatic
and GEF functions (Kang et al, 2014), which may give it a more
direct role in proliferation, cell adhesion, migration and invasion
(Chae et al, 2010).
The fact that a brief four hour exposure of cells to EVJ had
a damaging effect on colony formation 2 weeks later indicates
that short term inhibition of PLD1 has significant long term
effects on PCa cell viability. That subsequent colony formation by
PCa cells from three patients was more seriously affected by
initial EVJ treatment than the five others must reflect differences
such as stage of disease in the PCa biopsies from which the cells
were purified. Our observations on EVJ effects on colony
formation and cell viability suggest that this new specific PLD1
inhibitor has similar potential for treating PCa as already shown
for breast cancer models in mice (Scott et al, 2009). In this
connection, it is relevant that the antipsychotic agent halopemide,
on which these new inhibitors are based, is well tolerated in
humans and has been tested in clinical trials (Loonen and Soudijn,
1985; Lindsley and Brown, 2012). EVJ could be used as a
combination therapy alongside hormone/anti-androgen treatments
that target luminal cells in PCa. PLD inhibition has also been
shown to sensitise cancer cells to radiotherapy (Cheol Son et al,
2013) opening up further possible therapeutic applications.
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